Nutrient and genetic biomarkers of nutraceutical treatment response in mood and psychotic disorders: a systematic review

References

• Sarris J. Clinical use of nutraceuticals in the adjunctive treatment of depression in mood disorders. Australas Psychiatry. 2017;25(4):369–372.
   PubMed Web of Science ®Google Scholar
• Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Spencer D, Fava M. The STAR*D study: treating depression in the real world. Cleve Clin J Med. 2008;75(1):57–66.
   PubMed Web of Science ®Google Scholar
• Harrow M, Jobe TH. Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? Schizophr Bull. 2013; 39(5):962–965.
   PubMedGoogle Scholar
• Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47–53.
   PubMed Web of Science ®Google Scholar
• Pietrzak RH, Kinley J, Afifi TO, Enns MW, Fawcett J, Sareen J. Subsyndromal depression in the United States: prevalence, course, and risk for incident psychiatric outcomes. Psychol Med. 2013;43(7):1401–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23111093.
   PubMed Web of Science ®Google Scholar
• Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional Recovery from a first episode of schizophrenia or Schizoaffective disorder. Am J Psychiatry. 2004; 161(3):473–479.
   Web of Science ®Google Scholar
• De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012 Feb 18 [cited 2019 May 6];8(2):114–26. Available from: http://www.nature.com/articles/nrendo.2011.156
   Web of Science ®Google Scholar
• Sarris J, Kavanagh DJ, Byrne G. Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines. J Psychiatr Res. 2010;44:32–41.
   PubMed Web of Science ®Google Scholar
• Galizia I, Oldani L, Macritchie K, Amari E, Dougall D, Jones TN, et al. S-adenosyl methionine (SAMe) for depression in adults. Cochrane Database Syst Rev. 2016; 161(3):473–479.
   Web of Science ®Google Scholar
• Bozzatello P, Brignolo E, De Grandi E, Bellino S. Supplementation with omega-3 fatty acids in psychiatric disorders: A review of literature data. J Clin Med. 2016; 5(8):67.
   PubMed Web of Science ®Google Scholar
• Williams AL, Girard C, Jui D, Sabina A, Katz DL. S-adenosylmethionine (SAMe) as treatment for depression: a systematic review. Clin Invest Med. 2005;28(3):132–9.
   PubMed Web of Science ®Google Scholar
• Sarris J, Murphy J, Mischoulon D, Papakostas GI, Fava M, Berk M, et al. Adjunctive nutraceuticals for Depression: A systematic review and Meta-analyses. Am J Psychiatry. 2016 Jun 26 [cited 2019 Feb 1];173(6):575–87. Available from: http://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2016.15091228.
   PubMed Web of Science ®Google Scholar
• Bertone-Johnson ER. Vitamin D and the occurrence of depression: causal association or circumstantial evidence? Nutr Rev. 2009;67(8):481–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19674344.
   PubMed Web of Science ®Google Scholar
• Chambial S, Dwivedi S, Shukla KK, John PJ, Sharma P. Vitamin C in disease prevention and cure: an overview. Indian J Clin Biochem. 2013;28(4):314–28. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24426232.
   PubMedGoogle Scholar
• Strawbridge R, Young AH, Cleare AJ. Biomarkers for depression: recent insights, current challenges and future prospects. Neuropsychiatr Dis Treat. 2017; 13:1245.
   PubMed Web of Science ®Google Scholar
• Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker R, et al. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry. 2015;21(1):71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25802980
   PubMed Web of Science ®Google Scholar
• Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the Tumor Necrosis Factor Antagonist Infliximab for treatment-Resistant Depression. JAMA Psychiatry. 2013;70(1):31–41.
   PubMed Web of Science ®Google Scholar
• Hill M, Shannahan K, Jasinski S, Macklin EA, Raeke L, Roffman JL, et al. Folate supplementation in schizophrenia: A possible role for MTHFR genotype. Schizophr Res. 2011 ;127(1–3):41–45.
   Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009; 6(7):e1000100.
   Google Scholar
• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996; 17(1):1–12.
   PubMedGoogle Scholar
• Ganança L, Galfalvy HC, Oquendo MA, Hezghia A, Cooper TB, Mann JJ, et al. Lipid correlates of antidepressant response to omega-3 polyunsaturated fatty acid supplementation: A pilot study. Prostaglandins Leukot Essent Fat Acids. 2017; 119:38–44.
   PubMed Web of Science ®Google Scholar
• Freeman MP, Hibbeln JR, Silver M, Hirschberg AM, Wang B, Yule AM, et al. Omega-3 fatty acids for major depressive disorder associated with the menopausal transition: A preliminary open trial. Menopause. 2011; 18(3):279.
   Web of Science ®Google Scholar
• Jiang W, Whellan DJ, Adams KF, Babyak MA, Boyle SH, Wilson JL, et al. Long-Chain omega-3 fatty acid Supplements in depressed heart failure patients: results of the OCEAN trial. JACC Hear Fail. 2018; 6(10):833–843.
   PubMedGoogle Scholar
• Clayton EH, Hanstock TL, Hirneth SJ, Kable CJ, Garg ML, Hazell PL. Reduced mania and depression in juvenile bipolar disorder associated with long-chain ω-3 polyunsaturated fatty acid supplementation. Eur J Clin Nutr. 2009 ;63(8):1037.
   PubMed Web of Science ®Google Scholar
• Nishi D, Su KP, Usuda K, Chang JPC, Hamazaki K, Ishima T, et al. Plasma estradiol levels and antidepressant effects of omega-3 fatty acids in pregnant women. Brain Behav Immun. 2019.
   PubMed Web of Science ®Google Scholar
• Ganança L, Galfalvy HC, Oquendo MA, Hezghia A, Cooper TB, Mann JJ, et al. Lipid correlates of antidepressant response to omega-3 polyunsaturated fatty acid supplementation: A pilot study. Prostaglandins Leukot Essent Fat Acids. 2017 ;119:38–44.
   PubMed Web of Science ®Google Scholar
• Carney RM, Steinmeyer BC, Freedland KE, Rubin EH, Rich MW, Harris WS. Baseline blood levels of omega-3 and depression remission: A secondary analysis of data from a placebo-controlled trial of omega-3 supplements. J Clin Psychiatry. 2016; 77(2):e138.
   PubMed Web of Science ®Google Scholar
• Freeman MP, Hibbeln JR, Silver M, Hirschberg AM, Wang B, Yule AM, et al. Omega-3 fatty acids for major depressive disorder associated with the menopausal transition: a preliminary open trial. Menopause. 2011; 18(3):279.
   Web of Science ®Google Scholar
• Arnold LE, Young AS, Belury MA, Cole RM, Gracious B, Seidenfeld AM, et al. Omega-3 fatty acid plasma levels before and after supplementation: correlations with mood and clinical outcomes in the omega-3 and therapy studies. J Child Adolesc Psychopharmacol. 2017; 27(3):223–233.
   Web of Science ®Google Scholar
• Qiao Y, Mei Y, Han H, Liu FJ, Yang XM, Shao Y, et al. Effects of omega-3 in the treatment of violent schizophrenia patients. Schizophr Res. 2018; 195:283–285.
   PubMedGoogle Scholar
• Bentsen H, Landrø NI. Neurocognitive effects of an omega-3 fatty acid and vitamins E + C in schizophrenia: A randomised controlled trial. Prostaglandins Leukot Essent Fat Acids. 2018; 136:57–66.
   PubMed Web of Science ®Google Scholar
• Bentsen H, Osnes K, Refsum H, Solberg DK, Bøhmer T. A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E + C in schizophrenia. Transl Psychiat. 2013; 3(12):e335.
   PubMed Web of Science ®Google Scholar
• Van Rensburg SJ, Smuts CM, Hon D, Kidd M, Van Der Merwe S, Myburgh C, et al. Changes in erythrocyte membrane fatty acids during a clinical trial of eicosapentaenoic acid (EPA) supplementation in schizophrenia. Metab Brain Dis. 2009;24(4):659.
   PubMed Web of Science ®Google Scholar
• Nishi D, Su K-P, Usuda K, Chang JP-C, Hamazaki K, Ishima T, et al. Plasma estradiol levels and antidepressant effects of omega-3 fatty acids in pregnant women. Brain Behav Immun. 2019 Feb 15 [cited 2019 May 8]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30776476.
   PubMed Web of Science ®Google Scholar
• Clayton EH, Hanstock TL, Hirneth SJ, Kable CJ, Garg ML, Hazell PL. Reduced mania and depression in juvenile bipolar disorder associated with long-chain omega-3 polyunsaturated fatty acid supplementation. Eur J Clin Nutr. 2009;63(8):1037–40.
   PubMed Web of Science ®Google Scholar
• Sarris J, Byrne GJ, Bousman C, Stough C, Murphy J, MacDonald P, et al. Adjunctive S-adenosylmethionine (SAMe) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial. Eur Neuropsychopharmacol. 2018; 28(10):1126–1136.
   PubMed Web of Science ®Google Scholar
• Bedson E, Bell D, Carr D, Carter B, Hughes D, Jorgensen A, et al. Folate augmentation of treatment–evaluation for Depression (FolATED): randomised trial and economic evaluation. Health Technol Assess. 2014; 18(48):vii.
   PubMed Web of Science ®Google Scholar
• Sarris J, Papakostas G I, Vitolo O, Fava M, Mischoulon D. S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. J Affect Disord. 2014; 164:76–81.
   PubMed Web of Science ®Google Scholar
• Mischoulon D, Alpert JE, Arning E, Bottiglieri T, Fava M, Papakostas GI. Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder. J Clin Psychiat. 2012; 73(6):843.
   Google Scholar
• Alpert JE, Mischoulon D, Rubenstein GE, Bottonari K, Nierenberg AA, Fava M. Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiat. 2002;14(1):33–8. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12046638.
   PubMedGoogle Scholar
• Allott K, McGorry PD, Yuen HP, Firth J, Proffitt TM, Berger G, et al. The vitamins in psychosis study: A randomized, Double-blind, placebo-controlled trial of the effects of vitamins B 12, B 6, and folic acid on symptoms and neurocognition in first-episode psychosis. Biol Psychiat. 2019.
   PubMedGoogle Scholar
• Roffman JL, Petruzzi LJ, Tanner AS, Brown HE, Eryilmaz H, Ho NF, et al. Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: A randomized controlled trial. Mol Psychiat. 2018; 23(2):316.
   PubMed Web of Science ®Google Scholar
• Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, et al. Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiat. 2013; 70(5):481–489.
   PubMed Web of Science ®Google Scholar
• Dakhale GN, Khanzode SD, Khanzode SS, Saoji A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology (Berl). 2005; 182(4):494–498.
   PubMed Web of Science ®Google Scholar
• Alavi NM, Khademalhoseini S, Vakili Z, Assarian F. Effect of vitamin D supplementation on depression in elderly patients: A randomized clinical trial. Clin Nutr. 2018 Sep [cited 2019 May 8]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S026156141832449X
   PubMedGoogle Scholar
• Mozaffari-Khosravi H, Nabizade L, Yassini-Ardakani SM, Hadinedoushan H, Barzegar K. The effect of 2 different single injections of high dose of vitamin D on improving the depression in depressed patients with vitamin D deficiency: A randomized clinical trial. J Clin Psychopharmacol. 2013; 33(3):378–385.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang S, Zhu Y, Yang T. Vitamin D3 as adjunctive therapy in the treatment of depression in tuberculosis patients: A short-term pilot randomized double-blind controlled study. Neuropsychiatr Dis Treat. 2018;14:3103.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu Y, Lian Y, Li N, Liu H, Li G. Efficacy of high-dose supplementation with oral vitamin d3 on depressive symptoms in dialysis patients with vitamin d3 insufficiency a prospective, randomized, double-blind study. J Clin Psychopharmacol. 2016; 36(3):229–235.
   Web of Science ®Google Scholar
• Sepehrmanesh Z, Kolahdooz F, Abedi F, Mazroii N, Assarian A, Asemi Z, et al. Vitamin D supplementation Affects the Beck Depression Inventory, Insulin Resistance, and biomarkers of oxidative stress in patients with major depressive disorder: A randomized, controlled clinical trial. J Nutr. 2015; 146(2):243–248.
   PubMed Web of Science ®Google Scholar
• Marsh WK, Penny JL, Rothschild AJ. Vitamin D supplementation in bipolar depression: A double blind placebo controlled trial. J Psychiatr Res. 2017; 95:48–53.
   PubMed Web of Science ®Google Scholar
• Ghaderi A, Banafshe HR, Mirhosseini N, Moradi M, Karimi MA, Mehrzad F, et al. Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients. BMC Psychiatry. 2019; 19(1):77.
   PubMed Web of Science ®Google Scholar
• Krivoy A, Onn R, Vilner Y, Hochman E, Weizman S, Paz A, et al. Vitamin D supplementation in Chronic schizophrenia patients treated with Clozapine: A randomized, Double-blind, placebo-controlled clinical trial. EBioMedicine. 2017; 26:138–145.
   PubMed Web of Science ®Google Scholar
• Sheikhmoonesi F, Zarghami M, Mamashli S, Charati JY, Hamzehpour R, Fattahi S, et al. Effectiveness of vitamin d supplement therapy in chronic stable schizophrenic male patients: A randomized controlled trial. Iran J Pharm Res. 2016; 15(4):941.
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Shelton RC, Zajecka JM, Bottiglieri T, Roffman J, Cassiello C, et al. Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J Clin Psychiat. 2014; 75(8):855–863.
   Web of Science ®Google Scholar
• Mech AW, Farah A. Correlation of clinical response with homocysteine reduction during therapy with reduced b vitamins in patients with mdd who are positive for MTHFR C677 T or A1298C polymorphism: A randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2016; 77(5):668–671.
   PubMed Web of Science ®Google Scholar
• Sarris J, Byrne GJ, Stough C, Bousman C, Mischoulon D, Murphy J, et al. Nutraceuticals for major depressive disorder- more is not merrier: An 8-week double-blind, randomised, controlled trial. J Affect Disord. 2019 Feb 15 [cited 2019 Feb 1];245:1007–15. Available from: https://www.sciencedirect.com/science/article/pii/S0165032718314113.
   PubMed Web of Science ®Google Scholar
• Zhilyaeva TV, Sergeyeva A V, Kasimova LN, Blagonravova AS. Cognitive function dynamics during folate augmented therapy in patients with schizophrenia carrying MTHFR677C > T gene polymorphism: A pilot study. Sovrem Tehnol v Med. 2015;7(4).
   PubMed Web of Science ®Google Scholar
• Ellingrod VL, Grove TB, Burghardt KJ, Taylor SF, Dalack G. The effect of folate supplementation and genotype on cardiovascular and epigenetic measures in schizophrenia subjects. npj Schizophr. 2015; 1:15046.
   PubMed Web of Science ®Google Scholar
• Grosso G, Galvano F, Marventano S, Malaguarnera M, Bucolo C, Drago F, et al. Omega-3 fatty acids and depression: Scientific evidence and biological mechanisms. Oxid Med Cell Longevity. 2014; 2014. doi:10.1155/2014/313570.
   PubMed Web of Science ®Google Scholar
• Frodl T. Recent advances in predicting responses to antidepressant treatment. F1000Res. 2017;6.
   Google Scholar
• Benton D. To establish the parameters of optimal nutrition do we need to consider psychological in addition to physiological parameters? Mol Nutr Food Res. 2013; 57(1):6–19.
   PubMed Web of Science ®Google Scholar